WAM
TCRT icon

Wolverine Asset Management’s Alaunos Therapeutics TCRT Stock Holding History

Wolverine Asset Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Hold
0
– -$4K – 1977
2015
Q2 		– Hold
0
– – – 1700

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wolverine Asset Management's TCRT Position: Q3 2016 in Review

Wolverine Asset Management sold out of Alaunos Therapeutics (TCRT) in Q3 2016, closing a stake of 13 shares — an estimated $10K sold.

Wolverine Asset Management first reported a position in TCRT in Q4 2014 and held it in 6 quarters. The position peaked at $356K in Q3 2015. 140 funds tracked by Wall St. Rank hold TCRT as of Q3 2016.

  • Wolverine Asset Management reported no remaining Alaunos Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Wolverine Asset Management sold 13 Alaunos Therapeutics shares in Q3 2016, an estimated $10K.
  • Wolverine Asset Management first reported a position in Alaunos Therapeutics in Q4 2014 and held it in 6 quarters.
  • Wolverine Asset Management's Alaunos Therapeutics position peaked at $356K in Q3 2015.
  • 140 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2016.

Based on Wolverine Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.